Waypoint Bio's innovative approach to leveraging spatial biology in pooled screening is a significant leap forward in the field of cell therapy for solid tumors. The ability to conduct high-throughput, in vivo screens and measure complex phenotypes at the single-cell level can accelerate the discovery of effective treatments for challenging diseases like pancreatic cancer. This substantial seed funding will enable Waypoint to advance its CAR T-cell and Treg therapy programs, potentially transforming the landscape of cancer treatment and autoimmune disease management. The expertise and unique backgrounds of the founders, combined with the support from notable investors and advisors, position Waypoint Bio as a promising leader in the biotechnology sector.